Affinity Asset Advisors LLC Sells 2,300,000 Shares of Taysha Gene Therapies, Inc. $TSHA

Affinity Asset Advisors LLC lowered its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 69.7% during the first quarter, HoldingsChannel.com reports. The fund owned 1,000,000 shares of the company’s stock after selling 2,300,000 shares during the quarter. Affinity Asset Advisors LLC’s holdings in Taysha Gene Therapies were worth $4,470,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. AQR Capital Management LLC raised its position in shares of Taysha Gene Therapies by 325.6% in the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock worth $150,000 after acquiring an additional 82,545 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Taysha Gene Therapies by 13.5% during the 2nd quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock valued at $539,000 after purchasing an additional 27,794 shares in the last quarter. Prudential Financial Inc. boosted its position in shares of Taysha Gene Therapies by 50.5% during the 2nd quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock valued at $53,000 after purchasing an additional 7,650 shares in the last quarter. Invesco Ltd. increased its holdings in Taysha Gene Therapies by 27.4% in the second quarter. Invesco Ltd. now owns 203,671 shares of the company’s stock worth $470,000 after purchasing an additional 43,772 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Taysha Gene Therapies in the second quarter worth approximately $184,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on TSHA. Citizens Jmp restated a “market outperform” rating and set a $11.00 price target on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, June 30th. BMO Capital Markets raised their price objective on Taysha Gene Therapies from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, June 23rd. Finally, Pivotal Research set a $14.00 target price on Taysha Gene Therapies in a research report on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Taysha Gene Therapies currently has an average rating of “Buy” and a consensus price target of $12.77.

Taysha Gene Therapies Stock Down 5.3%

Taysha Gene Therapies stock opened at $5.52 on Friday. Taysha Gene Therapies, Inc. has a fifty-two week low of $2.53 and a fifty-two week high of $7.30. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04. The firm’s 50-day simple moving average is $5.97 and its 200 day simple moving average is $5.36. The stock has a market cap of $1.59 billion, a PE ratio of -14.53 and a beta of 1.17.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Research analysts predict that Taysha Gene Therapies, Inc. will post -0.49 EPS for the current fiscal year.

Insider Activity

In related news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the completion of the transaction, the insider owned 936,410 shares in the company, valued at approximately $5,843,198.40. This represents a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is currently owned by corporate insiders.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.